Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Neural Correlates of Hypoalgesia Driven by Observation

NCT03897998
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo
Interventions
Naloxone, Saline
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults

NCT03603665
View directory record Official record
Conditions
Botulism
Interventions
NTM-1633, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818
View directory record Official record
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Vitamin B12 Treatment in Singers

NCT03437824
View directory record Official record
Conditions
Vitamin B 12 Deficiency
Interventions
Cyanocobalamin, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 14 Years
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Mobile, Alabama • San Diego, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 3 Interventional

Intranasal Civamide for Episodic Cluster Headache

NCT00069082
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Civamide (Zucapsaicin), Sodium Chloride
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans

NCT02537314
View directory record Official record
Conditions
Obesity
Interventions
benzocaine, placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Active, not recruiting Phase 2 Interventional

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

NCT05866536
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions
Bacillus Calmette-Guérin, Saline Injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
View directory record Official record
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

NCT01622348
View directory record Official record
Conditions
Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
13
States / cities
Jacksonville, Florida • Alpharetta, Georgia • Macon, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07489651
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
RE104 for Injection, Placebo
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 74 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated Phase 4 Interventional Results available

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

NCT01250496
View directory record Official record
Conditions
Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Post-Operative Treatment With Ketorolac After Abdominal Myomectomy

NCT00845754
View directory record Official record
Conditions
Febrile Morbidity, Pain
Interventions
ketorolac, saline
Drug
Lead sponsor
Ascher-Walsh, Charles, M.D.
Individual
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

NCT03821402
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
26
States / cities
Downey, California • Fountain Valley, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

NCT01843790
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
GCS-100, Placebo, Saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion

NCT02061774
View directory record Official record
Conditions
Low Back Pain
Interventions
Acetaminophen, Placebo comparator
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

NCT03070782
View directory record Official record
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Interventions
ISIS 681257, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Results available

The Effect of N115 on Coughing in IPF Patients

NCT06037408
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
Drug · Other
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hialeah Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2Phase 3 Interventional

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

NCT02427191
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
AmnioFix® Injectable, Saline Injection
Other · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 79 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Fresno, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 1 Interventional

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

NCT03556007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 15, 2026, 1:41 AM EDT